Infinitus, a specialist in Chinese herbal medicine, has successfully passed an on-site evaluation at one of its laboratory sites.
The inspection was carried out by the Chinese National Accreditation Service for Conformity Assessment (CNAS), and is the third recognition for the company by the regulator.
CNAS is recognised and authorised by the National Certification and Accreditation Administration, and oversees the accreditation of laboratories, inspection centres and allied institutions.
The reports are universally recognised in a range of countries worldwide, as well as having legal weight in China.
Infinitus' global R&D centre has an array of laboratories on its grounds which specialist in Chinese herbal medicine quality assurance, chromatography and spectrum analysis, as well as high-temperature testing.
According to the company, the laboratories tested passed proficiency tests assigned by stringent global bodies, such as the UK's FAPAS scheme and the US Pharmacopeia.
Infinitus' CEO, Lam Yu, commented on the evaluation: "For Infinitus, enhancing our core capabilities stands as not only the cornerstone for differentiating our products in a competitive landscape, but also a solid foundation for ongoing innovation and sustainable growth. The CNAS accreditation will bolster user trust and confidence in our products and technologies,"
"The accreditation is just the starting point. The Infinitus Global R&D Center remains steadfast in its user-centric approach, committed to laying a robust foundation, augmenting core competencies, and forging a trust-based independent R&D and innovation path."